Dept. of Medicine II, Medical Center - University of Freiburg and Faculty of Medicine, University Hospital Freiburg, Freiburg, Germany; IMM-PACT Programm, Faculty of Medicine, University Hospital Freiburg, Freiburg, Germany.
Dept. of Medicine II, Medical Center - University of Freiburg and Faculty of Medicine, University Hospital Freiburg, Freiburg, Germany.
Curr Opin Virol. 2021 Dec;51:149-157. doi: 10.1016/j.coviro.2021.10.002. Epub 2021 Oct 26.
Chronic hepatitis B virus (HBV) infection is a major global health burden causing severe complications like liver cirrhosis or hepatocellular carcinoma. Curative treatment options are lacking. Therefore, there is an urgent need for new therapeutic options. Immunotherapy with the goal to restore dysfunctional HBV-specific T cell immunity is an interesting new therapeutic strategy. Based on current evidence on dysfunction of the HBV-specific CD8 T cell response in chronic HBV infection, we will review the growing field of immunotherapeutic approaches for treatment of chronic HBV infection. The review will focus on therapies targeting T cells and will cover checkpoint inhibitors, T cell engineering, Toll-like receptor agonists and therapeutic vaccination.
慢性乙型肝炎病毒 (HBV) 感染是一个全球性的健康负担,可导致严重并发症,如肝硬化或肝细胞癌。目前缺乏根治性治疗方法。因此,迫切需要新的治疗选择。免疫疗法旨在恢复功能失调的 HBV 特异性 T 细胞免疫,是一种很有前途的新治疗策略。基于目前慢性 HBV 感染中 HBV 特异性 CD8 T 细胞反应功能失调的证据,我们将综述慢性 HBV 感染治疗中免疫治疗方法的进展。综述将重点关注针对 T 细胞的治疗方法,包括检查点抑制剂、T 细胞工程、Toll 样受体激动剂和治疗性疫苗。